Recombinant Zoster Vaccine Timing Before Starting a JAK Inhibitor
A patient with active, erosive rheumatoid arthritis needs a JAK inhibitor that carries a well-documented shingles risk, and hasn’t yet completed his zoster vaccine series. Neither drug is optional — the disagreement is over how many weeks of delay the disease itself can actually afford.
P.O., a 58-year-old man, manages a small hardware store he took over from his father, and has spent the last four months increasingly unable to open the store's old manual cash drawer without help because of swelling and pain across both wrists and the small joints of his hands. He was diagnosed with seropositive rheumatoid arthritis five months ago, tried methotrexate at an adequate dose for three months with minimal response, and now has synovitis in fourteen joints, an elevated CRP, and early joint-space narrowing on hand films his rheumatologist reads as evidence of real, ongoing damage rather than just symptoms. He has never had shingles, has no history of immunocompromise before this diagnosis, and is otherwise healthy.
His rheumatologist wants to start tofacitinib now — the next appropriate step after methotrexate failure — but JAK inhibitors raise herpes zoster risk substantially, enough that rheumatology guidance recommends vaccinating before starting one, and he has not yet received recombinant zoster vaccine. RZV is a non-live, AS01B-adjuvanted subunit vaccine, so none of the live-vaccine timing restrictions that would apply to a live product apply here — but timing still matters for a different reason. ZOE-50 and ZOE-70, the trials that established RZV's efficacy, enrolled immunocompetent adults; at 58 he sits inside their age range but will not stay inside their immune profile for long, and what the series is worth when immunosuppression begins alongside it is not a question those trials were built to answer. The trial built for that question is STOP-HZ, which gave RA patients starting tofacitinib their two RZV doses on day 1 and at week 8 and randomized them to begin the drug immediately or to wait those eight weeks. Its result cuts against the intuition driving this visit. The immediate-start group did worse early — a meaningful antibody rise in 44.8 percent at week 4 against 80.0 percent in the delayed group — but by week 12 the two strategies were indistinguishable, a between-group ratio of 1.10. The head start is real, and it is temporary. ACIP permits an accelerated minimum interval of four weeks between doses for patients who are or will be immunosuppressed, against a standard two to six months, so a short delay is easy to schedule; what STOP-HZ does not settle is whether a transient week-4 advantage is worth four more weeks of erosion in fourteen inflamed joints.
Rheumatology and vaccinology, joint planning visit
Fourteen active joints with early erosive change on a background of methotrexate failure isn't a situation where I can ethically let a vaccine schedule set the treatment timeline. Every month of delay is measurable, potentially irreversible joint damage. And I don't think I'm trading away much to avoid it: STOP-HZ randomized this exact decision in patients starting tofacitinib and found the two strategies had converged by week 12, a between-group ratio of 1.10 with a confidence interval straddling one. I want tofacitinib started now, with RZV on the accelerated four-week interval running alongside it — not because the vaccine doesn't matter, but because the only trial that has actually compared these two schedules says the durable immunologic difference between them is somewhere between small and nothing.
I'll concede the week-12 endpoint, because it's the one you'd want if the question were his antibody titer next spring. It isn't. STOP-HZ's own week-4 data are the part that describes his actual exposure: 44.8 percent of the immediate-start patients had mounted a meaningful antibody rise, against 80.0 percent of those who waited. Zoster risk on a JAK inhibitor doesn't politely hold off until week 12 — it starts when the drug starts, and the early weeks are precisely when a concurrent-start patient is least protected. So I'm not claiming a permanently better immune response, which is what I think the standard argument for delay usually overclaims. I'm claiming a worse trough, in a window where he is exposed.
"Start together on the accelerated schedule" isn't the same thing as "start before" — the accelerated interval shortens the gap between his two vaccine doses, it doesn't move either dose ahead of the JAK inhibitor.
Then say that, and put it in the note, because the two of you have just agreed on the size of the thing you're arguing about — a deeper trough for a few weeks, not a permanently weaker vaccine — and that's a defensible reason to buy four weeks, in a way that "he'll respond better" would not have been. One caution about the plan as drafted, though. If we bridge those four weeks with a glucocorticoid course to keep his joints tolerable, we're suppressing the immune system we just delayed his DMARD to protect, and steroids on a JAK inhibitor are themselves associated with a further rise in zoster risk. Bridge him at the lowest dose that gets him through, or the delay quietly buys less than the trial says it does.
Agreed: RZV dose one given today, dose two scheduled at the accelerated four-week interval, and tofacitinib deliberately held those same four weeks — a specific, bounded delay the rheumatologist judged his current joint burden could tolerate, rather than an open-ended one. P.O. was given a bridging plan for the interim four weeks — a short glucocorticoid course at the lowest effective dose, deliberately capped after the primary care physician pointed out that bridging with a steroid partly suppresses the immune system the delay exists to protect.
Not agreed: whether even a four-week delay was truly justified given his erosive change on imaging. The rheumatologist, holding STOP-HZ's week-12 equivalence, remained uneasy about any delay at all and agreed to it explicitly as a compromise, not a change of clinical opinion — if his joint counts worsen meaningfully during the four weeks, the plan is to revisit starting tofacitinib early rather than hold the line on the vaccine schedule regardless of what happens clinically in the interim.